Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 16/20 | 0.59 |
| ▸ | DAO | P14920 | 1/20 | 0.59 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12011328 | 0.87 | MAPK1 (0.52) | HCAR2DAOHCAR3MAPK1CYTH3 | |
| SCHEMBL70577 | 0.85 | HCAR2 (0.59) | HCAR2DAOHCAR3MAPK1CYTH3 | |
| SCHEMBL1815487 | 0.83 | MAPK1 (0.48) | HCAR2DAOHCAR3MAPK1 | |
| Hydrochloric Acid SCHEMBL7723258 | 0.83 | HCAR2 (0.57) | HCAR2DAOHCAR3MAPK1CYTH3 | |
| SCHEMBL19987833 | 0.83 | HCAR2 (0.57) | HCAR2DAOHCAR3MAPK1CYTH3 | |
| Water SCHEMBL1267709 | 0.83 | HCAR2 (0.57) | HCAR2DAOHCAR3MAPK1CYTH3 | |
| Hydrochloric Acid SCHEMBL11595364 | 0.83 | HCAR2 (0.57) | HCAR2DAOHCAR3MAPK1CYTH3 | |
| SCHEMBL28638090 | 0.83 | HCAR2 (0.57) | HCAR2DAOHCAR3MAPK1CYTH3 | |
| SCHEMBL13279353 | 0.82 | MAPK1 (0.47) | HCAR2DAOHCAR3MAPK1 | |
| Ammonia Solution, Strong SCHEMBL28463590 | 0.81 | HCAR2 (0.55) | HCAR2DAOHCAR3MAPK1CYTH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121577799-A | Method for determining 5-acetyl-1H-pyrazole-3-carboxylic acid related substances | 江苏联环药业股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-118546091-A | 5-Acetyl-1H-pyrazole-3-carboxylic acid and preparation method and application thereof | 济南尚博医药股份有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-111138289-B | Compound and process for synthesizing 5-acetyl-1H-pyrazole-3-carboxylic acid by using same | 奥锐特药业(天津)有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-111138289-A | Compound and process for synthesizing 5-acetyl-1H-pyrazole-3-carboxylic acid by using same | 奥锐特药业(天津)有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-118546091-B | 5-Acetyl-1H-pyrazole-3-carboxylic acid and preparation method and application thereof | 济南尚博医药股份有限公司 | 2026-04-10 | — | — | CN | disclosed |
| CN-118546091-B | 5-Acetyl-1H-pyrazole-3-carboxylic acid and preparation method and application thereof | 济南尚博医药股份有限公司 | 2026-04-10 | — | — | CN | disclosed |
| CN-121673226-A | Preparation method of drug intermediate 5-acetyl-1H-pyrazole-3-carboxylic acid and compound | 湖北宇阳药业有限公司 | 2026-03-17 | — | — | CN | disclosed |
| CN-121673226-A | Preparation method of drug intermediate 5-acetyl-1H-pyrazole-3-carboxylic acid and compound | 湖北宇阳药业有限公司 | 2026-03-17 | — | — | CN | disclosed |
| CN-121577799-A | Method for determining 5-acetyl-1H-pyrazole-3-carboxylic acid related substances | 江苏联环药业股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-121577799-A | Method for determining 5-acetyl-1H-pyrazole-3-carboxylic acid related substances | 江苏联环药业股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-121577799-A | Method for determining 5-acetyl-1H-pyrazole-3-carboxylic acid related substances | 江苏联环药业股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-120058672-A | Halogenated pyridylcarboxylic acid ester derivative and application thereof | 贵州医科大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20140051708-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-20 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2012139930-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-18 | — | — | WO | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-20140051708-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K6 | HCAR2 3486/4885DAO 3149/4885HCAR3 3249/4885 |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | HCAR2 308/4885DAO 1554/4885HCAR3 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.